Journal
NITRIC OXIDE-BIOLOGY AND CHEMISTRY
Volume 19, Issue 2, Pages 133-137Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.niox.2008.04.009
Keywords
melanoma; nitrotyrosine; nitric oxide; biochemotherapy
Categories
Funding
- NCI NIH HHS [P50 CA093459-01A10003, P50 CA093459, R01 CA090282-05, R01 CA090282, R21 CA111369, P50 CA093459-01A10007, P50 CA093459-01A1, K22 CA097983] Funding Source: Medline
Ask authors/readers for more resources
Human melanoma tumors cells are known to express the enzyme, inducible nitric oxide synthase (MOS), which is responsible for cytokine induced nitric oxide (NO) production during immune responses. This constitutive expression of MOS in many patients' tumor cells, as well as its strong association with poor patient survival, have led to the consideration of iNOS as a molecular marker of poor prognosis, as well as a possible target for therapy. The expression of iNOS in patient tumors was found to associate with nitrotyrosine, COX2, pSTAT3, and arginase. Using human melanoma patients' samples as well as cell lines, we have further evidence supporting intracellular NO production by detection of nitrotyrosine and also by use of DAF-2DA staining. Experiments were performed to scavenge the endogenous NO (with c-PTIO) resulting in melanoma cell growth inhibition; this was restored with SIN-1 (NO and O2-donor) providing data to support a functional role of this gas. Our goal is to understand the aberrant biology leading to this curious phenomenon, and to regulate it in favor of patient treatments. (C) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available